MX2019013110A - Anticuerpo anti-semaforina 4d humano. - Google Patents

Anticuerpo anti-semaforina 4d humano.

Info

Publication number
MX2019013110A
MX2019013110A MX2019013110A MX2019013110A MX2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A MX 2019013110 A MX2019013110 A MX 2019013110A
Authority
MX
Mexico
Prior art keywords
semaphorin
antibody
human anti
diseases
sema4d
Prior art date
Application number
MX2019013110A
Other languages
English (en)
Spanish (es)
Inventor
S Smith Ernest
Zauderer Maurice
Paris Mark
G M Scrivens Maria
Cornelison Angelica
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of MX2019013110A publication Critical patent/MX2019013110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2019013110A 2017-05-05 2018-05-04 Anticuerpo anti-semaforina 4d humano. MX2019013110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501981P 2017-05-05 2017-05-05
PCT/US2018/031263 WO2018204895A1 (en) 2017-05-05 2018-05-04 Human anti-semaphorin 4d antibody

Publications (1)

Publication Number Publication Date
MX2019013110A true MX2019013110A (es) 2019-12-16

Family

ID=64016767

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013110A MX2019013110A (es) 2017-05-05 2018-05-04 Anticuerpo anti-semaforina 4d humano.
MX2023003519A MX2023003519A (es) 2017-05-05 2019-11-04 Anticuerpo anti-semaforina 4d humano.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023003519A MX2023003519A (es) 2017-05-05 2019-11-04 Anticuerpo anti-semaforina 4d humano.

Country Status (14)

Country Link
US (3) US11427634B2 (https=)
EP (1) EP3618865A4 (https=)
JP (3) JP7246320B2 (https=)
KR (1) KR102680924B1 (https=)
CN (1) CN110636858B (https=)
AU (2) AU2018261947B2 (https=)
BR (1) BR112019023138A2 (https=)
CA (1) CA3061963A1 (https=)
IL (1) IL270244B2 (https=)
MX (2) MX2019013110A (https=)
NZ (1) NZ758300A (https=)
SG (1) SG11201909466RA (https=)
WO (1) WO2018204895A1 (https=)
ZA (1) ZA201907148B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
BR112019001944A2 (pt) 2016-08-02 2019-05-07 Vaccinex, Inc. métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
CA3061963A1 (en) * 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
AU2020322474A1 (en) 2019-08-01 2022-03-10 Vaccinex,Inc. Combined inhibition of semaphorin-4D and TGFβ and compositions therefor
CN117597360A (zh) * 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用
JP2024535403A (ja) 2021-09-27 2024-09-30 バクシネックス インコーポレーティッド 神経変性障害を処置するための抗セマフォリン４ｄ結合分子の使用に関する予測アウトカムプロファイリング
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
KR102875105B1 (ko) * 2023-04-03 2025-10-21 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물
CN117924494B (zh) * 2024-01-23 2025-02-25 首都医科大学附属北京积水潭医院 特异性结合sema4d的抗原结合蛋白及其应用
WO2026030311A1 (en) 2024-07-29 2026-02-05 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules to treat cognitive impairment
WO2026080818A1 (en) 2024-10-10 2026-04-16 Vaccinex, Inc. Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
EP2032606B1 (en) 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
FI20075278A0 (fi) * 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
WO2008151204A1 (en) 2007-06-04 2008-12-11 Sequent Medical Inc. Methods and devices for treatment of vascular defects
AU2009294415B2 (en) * 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
MX343640B (es) 2011-05-13 2016-11-15 Nat Univ Corp Tokyo Medical & Dental Univ Promotor de osteogenesis.
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) * 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
CN104127862A (zh) * 2014-08-14 2014-11-05 武汉大学 Semaphorin 4D在预防及治疗骨代谢性疾病中的应用
EP3233915B1 (en) * 2014-12-15 2024-08-28 MorphoSys AG Antibodies for il-17c
CA3061963A1 (en) * 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
CN117597360A (zh) * 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用

Also Published As

Publication number Publication date
CN110636858B (zh) 2024-03-19
JP2024081694A (ja) 2024-06-18
US20220356249A1 (en) 2022-11-10
EP3618865A1 (en) 2020-03-11
EP3618865A4 (en) 2021-05-05
IL270244B2 (en) 2025-01-01
KR102680924B1 (ko) 2024-07-02
CA3061963A1 (en) 2018-11-08
KR20200004324A (ko) 2020-01-13
JP7460819B2 (ja) 2024-04-02
WO2018204895A1 (en) 2018-11-08
RU2019131732A (ru) 2021-06-07
US20240309091A1 (en) 2024-09-19
US20210032329A1 (en) 2021-02-04
NZ758300A (en) 2025-11-28
US12006365B2 (en) 2024-06-11
ZA201907148B (en) 2025-06-25
JP2023075271A (ja) 2023-05-30
JP7246320B2 (ja) 2023-03-27
IL270244A (en) 2019-12-31
AU2018261947B2 (en) 2024-06-13
BR112019023138A2 (pt) 2020-07-28
JP2020518248A (ja) 2020-06-25
MX2023003519A (es) 2023-04-19
CN110636858A (zh) 2019-12-31
US11427634B2 (en) 2022-08-30
IL270244B1 (en) 2024-09-01
SG11201909466RA (en) 2019-11-28
AU2024204752A1 (en) 2024-08-01
RU2019131732A3 (https=) 2021-09-28
AU2018261947A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
MX2023003519A (es) Anticuerpo anti-semaforina 4d humano.
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
MX2022010224A (es) Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12017501402A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
MX2022014762A (es) Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso.
MY203971A (en) Anti-lag-3 antibodies and compositions
WO2016086175A8 (en) Effector-deficient anti-cd32a antibodies
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX385868B (es) Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
WO2018134681A8 (en) Anti-tgf-beta antibodies and their use
IL281441B (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
HK1255056A1 (zh) 抗cd115抗体
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
HK40038634A (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
HK40039204A (en) Anti-ifnar1 antibodies for treating autoimmune diseases